# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹2,290 Cr** Q4 FY26 (+19%) · **₹8,280 Cr** FY26 (+14%) * **EBITDA:** **₹363 Cr** Q4 FY26 (+2%) · **₹1,326 Cr** FY26 (+8%) * **Normalized PAT:** **₹129 Cr** Q4 FY26 (YoY decrease) · **₹442 Cr** FY26 (+7%) * **Net Debt:** **₹1,952 Cr** current ## B. Revenue & Profitability Drivers * **Segment Momentum:** Robust top-line growth driven by Radiopharma, Allergy Immunotherapy, and CDMO Sterile Injectables, with the latter showing particular strength over the full year. * **Margin Compression:** Profitability margins were pressured by SPECT product supply shortages and cost under-absorption at the Montreal facility. * **Mix Dynamics:** Overall margins are being impacted by a shift toward the **Ruby-Fill® franchise**, which carries a lower margin profile than the SPECT franchise. * **Montreal Turnaround:** The Montreal plant incurred a significant EBITDA loss of **₹200 Cr** last year; however, aggressive cost-cutting is expected to meaningfully reduce P&L losses in the coming year. * **Tax & API Outlook:** The current high tax rate of **33%** is expected to soften as PBT improves; meanwhile, API margins are poised for expansion driven by custom manufacturing growth. ## C. Cash Flow & Capital Allocation * **Investment Discipline:** Capital allocation across all core segments is strictly governed by a value-accretive **ROCE threshold**. * **FCF Inflection:** Positive free cash flow is anticipated by **FY2027**, catalyzed by commercial production on Line 3 and tech transfer revenue from Line 4. ## D. Balance Sheet Strategy * **Deleveraging Roadmap:** Management has committed to a "Net Debt Zero" target by **FY2030**. * **Debt Reduction Timeline:** Visible reductions in net debt are projected to commence in **FY2028** as EBITDA scales from new production lines. --- # 2. Manufacturing & Capacity ## A. Key Figures * **FY2026 Capex:** **₹1,668 Cr** Total Investment * **Line 3 Revenue:** **$60M–$80M** FY2027 Projection · **$80M–$90M** Accelerated Peak Potential * Projected EBITDA Margin: 17%–18% in H2 FY2027 ## B. Facility Utilization & Tech Transfers * **Accelerated Commercialization:** Line 3 is tracking to reach peak revenue roughly **two years ahead of schedule**, catalyzed by the transition of a top-10 global oncology product to commercial status. * **Robust Pipeline Activity:** Over **10 products** are currently in tech transfer for Line 3; commercial production is slated for late FY2027 following regulatory clearance. * **Radiopharmaceutical Expansion:** The company is commercializing its first **three PET radiopharmacies** in the coming year, with cyclotrons expected to reach peak dose production within a three-to-four-year window. * **Custom Manufacturing Readiness:** Management confirmed significant available capacity to support large-scale custom manufacturing contracts for innovator pharmaceutical clients. ## C. Capital Expenditure & Infrastructure * **Sustained Investment Levels:** Capex for FY2027 is expected to mirror the previous year's robust spending to finalize high-value sterile injectable and biologics infrastructure. * **Strategic Focus:** Large-scale spending over the next 18 months is strictly disciplined, focusing on completing state-of-the-art isolator fill-finish lines in Spokane and Montreal. * **Asset Transition:** The radiopharmaceutical pipeline has been successfully migrated to a third-party CMO network, with two non-MIBG products expected to reach the exhibit batch stage this year. ## D. Production Stabilization & Margins * **Profitability Inflection:** While Line 3 margins will initially track with the broader Spokane business as costs are realized, significant expansion is anticipated post-FY2027 as utilization peaks. * **Montreal Recovery:** Profitability at the Montreal site remains contingent on the Line 5 ramp-up; however, margins are expected to strengthen significantly in late FY2027 as operations stabilize. --- # 3. Product & Segment Performance ## A. Key Figures * **Radiopharma Guidance:** **Low double-digit** Revenue Growth · **38% to 42%** Margins * SPECT Revenue Impact: ~$14M H1 headwind * **Ruby-Fill Growth:** **30%+** * **Generics Performance:** **13%** Revenue Growth · **250%** Margin Expansion * **Allergy Growth:** **12%** FY2026 (vs. 3% FY2025) * **Discovery Revenue:** **₹650 Cr+** (+15%) ## B. Radiopharma Portfolio * **Ruby-Fill Momentum:** Robust expansion in market share and pricing, supported by a **10%** underlying market growth rate and favorable US reimbursement. * **Temporary SPECT Headwinds:** Significant H1 revenue impact noted due to high-margin product constraints; however, production is slated to normalize in H2. * **Portfolio Expansion:** Successful onboarding of a large oncology product strengthens the pipeline of high-value biologic assets. ## C. Allergy & Generics * **Generics Profitability:** Strong top-line growth paired with massive margin expansion, successfully pivoting the segment to double-digit EBITDA margins. * **Allergy Market Mix:** Revenue remains heavily US-centric (**~90%**), though recent growth acceleration is increasingly driven by non-US volume gains. ## D. Discovery Services * **Scaling Discovery:** Double-digit revenue growth achieved with proportionate increases in EBITDA and margins. * **API Strategy:** Active onboarding of custom manufacturing and New Chemical Entity (NCE) clients to optimize future capacity utilization and profitability. --- # 4. Commercial & Market Strategy ## A. Key Figures * **Market Share & Growth:** **80%** of Line 3 pipeline consists of complex biologics · **3% to 5%** US allergy market growth rate * **Operational Cadence:** **6 to 7 weeks** recurring generator replacement cycle ## B. Customer & Competitive Dynamics * **High-Moat Business Model:** Utilization of a "razor-blade" strategy ensures consistent recurring revenue, while the focus on complex biologics enables **price premiums** and high switching costs. * **Market Segmentation:** While large pharma faces heightened competition, the biotech segment is poised for recovery as **patent cliffs** drive capital toward innovator pipelines. * **Operational Leverage:** Support infrastructure for Ruby-Fill® is achieving greater efficiency and scale as geographic installation density increases. * **Market Outperformance:** The US allergy business is currently capturing market share, growing at a rate superior to the broader industry. ## C. Strategic Initiatives & Growth * **Independent Commercialization:** Management plans to launch MIBG internally, bypassing licensing to leverage existing radiopharmacy capabilities and downstream expertise. * **Expansion Levers:** Growth strategy focuses on penetrating the low-share European market and executing business development for adjacent products to maximize sales force productivity. --- # 5. Pricing & Regulatory Risks ## A. Supply & Margin Outlook * **Temporary Margin Compression:** Profitability in H1 FY2027 will be pressured by a supply shortage of the company’s highest-margin SPECT cold kits. * **Recovery Timeline:** Manufacturing is currently underway at the **Montreal CMO**; a return to regular run rates and margin uplift is expected in Q3 and Q4. * **Long-term Normalization:** While FY2027 performance will be depressed by these first-half supply constraints, management expects a full recovery to regular financial impact by **FY2028**. ## B. Pipeline & Regulatory Strategy * **MIBG Filing & Review:** The MIBG NDA filing is slated for **H2 FY2027**, with management targeting an accelerated **six-month** review timeline via its orphan drug designation. * **Incentive Uncertainty:** The company is evaluating eligibility for a **Priority Review Voucher (PRV)**, though the prior approval of a discontinued competitor product may complicate the application. * **Commercial Readiness:** Increased sales and marketing investments are planned to drive new NDAs toward peak potential; however, PET pharmacy timelines remain contingent on **FDA Pre-Approval Inspections (PAI)**. --- # 6. Guidance & Outlook ## A. Key Figures * **FY2027 Consolidated Growth:** **Low double-digit** * **FY2027 EBITDA Margin:** **38% to 40%** range * **Line 3 Revenue Target:** **₹8 Cr to ₹9 Cr** * **Long-term Margin Target:** **15%** aligned with 2030 vision ## B. FY2027 Projections * **Accelerated Asset Utilization:** Peak revenue for Line 3 is now anticipated **1.5 to 2 years** ahead of the original schedule. * **Phased Margin Recovery:** Profitability is expected to strengthen in H2 FY2027 as the **CMO Montreal** facility stabilizes, establishing a normalized run-rate for FY2028. * **Portfolio Optimization:** The entry of **innovator clients** in custom manufacturing is projected to enhance the API segment's margin profile starting in FY2027. ## C. Long-term Vision & Profitability * **Strategic Roadmap:** Management maintains a positive outlook for the discovery and generics segments as they progress toward **FY2030** commitments. * **Future Capacity Ramp:** Loss reduction is expected in **FY2028**, with Line 5 revenue contributions slated to begin in **FY2029** following media fills.